Systematic Identification and Assessment of Therapeutic Targets for Breast Cancer Based on Genome-Wide RNA...

Area of Science:

• Genomics
• Cancer Biology
• Bioinformatics

Background:

• Breast cancer exhibits significant genetic heterogeneity, complicating targeted therapy development.
• Identifying and prioritizing novel therapeutic targets remains a challenge due to the lack of systematic discovery and assessment methods.

Purpose of the Study:

• To develop and validate a systematic approach for identifying and prioritizing therapeutic targets in breast cancer.
• To leverage computational and multifaceted assessments for biological validation and therapeutic exploration.

Main Methods:

• Genome-wide RNA interference (RNAi) screening in MCF7 breast cancer cells to establish reference gene expression profiles.
• RNA-sequencing (RNA-seq) analysis of clinical breast cancer patient samples from The Cancer Genome Atlas (TCGA) to generate query signatures.
• Gene set enrichment analysis to identify genes whose knockdown reverses the breast cancer transcriptome.
• Multifaceted assessment for prioritizing gene therapy targets, drug repurposing, and identifying druggable proteins.

Main Results:

• Identified 510 genes whose knockdown significantly altered the breast cancer transcriptome.
• Prioritized potential therapeutic targets for gene therapy and identified novel drug repurposing opportunities.
• Generated a prioritized list of candidate therapeutic targets for luminal A, luminal B, HER2+, and triple-negative breast cancer subtypes.

Conclusions:

• The developed RNAi transcriptome-based approach provides a systematic paradigm for identifying and prioritizing breast cancer therapeutic targets.
• This method facilitates the discovery of novel targets and aids in selecting the most promising candidates for experimental validation and targeted therapy development.